2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1047 Tumor burden-dependent APRIL depletion undermines durable immunity in myeloma precursors and is reversed by BCMA-directed therapy

Noe Perron, PhD, Michelle Aranha, PhD2, Ting Wu, PhD3, Lorena Pantano, PhD4, Elizabeth D Lightbody, PhD5, Riddhiman Saha6, Daniel Heilpern-Mallory7, Michael Agius, PhD8, Saveliy Belkin, PhD9, Radoslaw Nowak10, Jacqueline Perry, MPH11, Erica Horowitz, BA12, Mark Hamilton, PhD13, Daniel Auclair14, Hearn Cho, MD, PhD15, George Mulligan, PhD16, Eric S Fischer, PhD17, Omar Nadeem, MD18, Catherine Marinac, PhD19, Lorenzo Trippa, PhD20, Gaddy Getz, PhD21, Romanos Sklavenitis Pistofidis, MD22, Irene M Ghobrial, MD23, Yoshinobu Konishi, MD, PhD24
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Multiple Myeloma Research, Norwalk, Connecticut, United States
14 Multiple Myeloma Research, Norwalk, Connecticut, United States
15 Multiple Myeloma Research, Norwalk, Connecticut, United States
16 Multiple Myeloma Research, Norwalk, Connecticut, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

INTRODUCTION

Multiple myeloma (MM) is preceded by the asymptomatic precursor states monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM), which affect 3-5% of adults over 50 and are now the target population for early cancer-interception vaccines and immunotherapies. Infection is a leading cause of death across the myeloma spectrum, frequently exceeding disease progression. Whether precursor patients can generate and maintain protective immunity, what drives any defect, and whether it can be reversed remain undefined.

METHODS

We established IMPACT (Immune Profiling and COVID-19 Trajectory), a prospective cohort of 731 participants (healthy donors [HD], 129; MGUS, 249; SMM, 273; MM, 80), using SARS-CoV-2 mRNA vaccination as a standardized antigenic challenge alongside childhood measles, mumps, and rubella (MMR) serology to separate de novo priming from long-term maintenance. Integrated profiling included 1,940 spike-specific IgG ELISAs, single-cell RNA sequencing (1,109,633 peripheral blood mononuclear cells; n=114), single-cell T-cell receptor sequencing (n=82), Olink plasma proteomics (n=50), and IFN-γ ELISPOT. To test reversibility, we profiled paired pre- and post-treatment plasma from 10 high-risk SMM patients receiving single-agent teclistamab (a BCMA-directed T-cell engager) on the Immuno-PRISM trial (NCT05469893) for APRIL, BAFF, and soluble BCMA (sBCMA). Disease-versus-HD contrasts were adjusted for age and sex.

RESULTS

Humoral immunity failed at the level of maintenance. Vaccine-induced antibodies waned approximately twice as fast in SMM as in MGUS (β = -0.0084 vs -0.0044 log-titer/day) and were not rescued by a third dose. Most strikingly, decades-old immunity was eroding during the clinically silent phase: SMM patients had reduced antibody titers to childhood mumps (q=0.007) and rubella (q=0.021) vaccines, implicating loss of long-lived plasma cells rather than impaired de novo generation. Plasma proteomics identified a unifying driver: APRIL, the principal survival cytokine of long-lived plasma cells, was progressively depleted across HD < MGUS < SMM (post-vaccination q=0.013) and correlated near-perfectly with tumor burden (Spearman ρ = -0.96, p < 0.001). Myeloid TNFSF13 (APRIL) transcription was intact in blood and marrow, indicating consumption by the expanding BCMA-positive clonal compartment rather than reduced production; an APRIL-responsive survival module was downregulated in normal B cells of SMM (p=0.007) and replicated in an independent bone-marrow plasma-cell cohort (p=0.002). This driver was pharmacologically reversible: in high-risk SMM, immunotherapy-mediated clearance of the BCMA-positive compartment (sBCMA down approximately 39-fold) released the sequestered ligands, with plasma APRIL rising approximately 2.8-fold and BAFF approximately 16-fold (all q=0.003; concordant in 10 of 10 patients, all achieving at least very good partial response). The deficit extended beyond antibodies. SMM patients failed to expand vaccine-specific T-cell clonotypes (HD expanded, p=0.037; SMM did not, p=0.2) while responses to unrelated viral antigens were preserved, and IFN-γ ELISPOT confirmed reduced spike-specific T-cell activation in SMM (p=0.004) with intact control responses (p=0.54). Post-vaccination induction of innate mediators (IL-1β, IL-18, RIG-I, NUB1, MMP7) was robust in HD (effect sizes r=0.82-0.88) but progressively lost across MGUS and SMM. Across independent endpoints, immune dysfunction scaled monotonically with disease stage.

CONCLUSIONS

Myeloma precursors harbor a multilayered, disease-burden-graded immune deficit unified by tumor-burden-dependent depletion of APRIL by the BCMA-positive clonal compartment, which undermines lifelong humoral memory while blunting de novo T-cell and innate responses. Critically, BCMA-directed therapy reverses the APRIL depletion that underlies this defect, nominating the APRIL-BCMA axis as a tractable target to restore immune competence. These findings reframe MGUS and SMM as states of active, reversible immune collapse years before diagnosis, with direct implications for the timing and design of cancer-interception vaccines, adjuvant selection, and infection prevention.

Noe Perron, PhD: No relevant conflicts of interest to declare.